Cost Effectiveness of the 13-Valent Pneumococcal Conjugate Vaccination Program in Chronic Obstructive Pulmonary Disease Patients Aged 50+ Years in Spain

摘要: Patients with chronic obstructive pulmonary disease (COPD) are at elevated risk of pneumococcal infection. A 13-valent conjugate vaccine (PCV13) was approved for protection against invasive and pneumonia caused by Streptococcus pneumoniae in adults. This study estimated the incremental cost-effectiveness ratio (ICER) vaccinating COPD patients ≥50 years old PCV13 compared current vaccination policy (CVP) 23-valent polysaccharide vaccine. Markov model accounting risks costs all-cause non-bacteremic (NBP) (IPD) developed. All parameters, such as incidence (€; 2015 values), were based on published data. The perspective analysis that Spanish National Healthcare System, horizon evaluation lifetime base case. Vaccine effectiveness considered waning effect over time. Outcomes both discounted 3 % annually. Over a 629,747 total population, would prevent 2224 cases inpatient NBP, 3134 outpatient 210 IPD extra comparison CVP. Additionally, 398 related deaths be averted. ICER €1518 per quality-adjusted life-year (QALY) gained versus found to cost effective CVP from 5-year modelling (1302 NBP 1835 together 182 prevented [ICER €25,573/QALY]). Univariate probabilistic sensitivity analyses confirmed robustness model. At commonly accepted willingness-to-pay threshold €30,000/QALY gained, patients aged ≥50 years cost-effective strategy 5 years Spain.